Core Viewpoint - Nohow Health is set to have its listing status canceled by the Hong Kong Stock Exchange effective October 27, 2025, due to failure to resume trading by the stipulated deadline [1][9]. Group 1: Company Overview - Nohow Health focuses on home early screening and genetic testing services for cancers prevalent among the Chinese population, covering three of the top ten cancers: colorectal cancer, gastric cancer, and cervical cancer [2]. - The company went public on the Hong Kong Stock Exchange in February 2021, raising a net amount of HKD 1.9 billion, with an opening price of HKD 76, representing a 185% increase from the issue price and a market capitalization exceeding HKD 30 billion [4]. Group 2: Financial Irregularities - In August 2023, Nohow Health faced allegations from short-seller CapitalWatch, claiming the company inflated revenues by over HKD 300 million in 2022 through practices such as pushing inventory to distributors and recognizing expired products as revenue [6]. - CapitalWatch estimated that Nohow Health's actual sales in 2022 were approximately HKD 76.95 million, nearly nine times lower than the reported HKD 765 million, suggesting a Ponzi-like scheme to maintain growth [6]. Group 3: Management Changes and Governance Issues - Following the financial irregularities, Nohow Health appointed independent non-executive directors and initiated an independent investigation, leading to the resignation of its auditor, Deloitte [10]. - The founder and CEO, Zhu Yeqing, resigned from his positions in December 2024 due to health reasons, and the board decided to hold a special meeting to remove him as an executive director, citing significant differences in management style [11][12]. Group 4: Market Impact - Nohow Health's shares have been suspended from trading since March 28, 2024, resulting in substantial losses for investors, with the last trading price at HKD 14.14 before suspension [9][13].